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terns of prescription drugs were analyzed using SAS statistical
software. RESULTS: A total of 3120 and 2791 patients with TC
were identiﬁed in 2000 and 2001 respectively. The overall trends
in 2000 were similar to those of 2001. In 2001, TC patients
visited their physician ofﬁce 1.3 times per year: 79% visited once
a year, 15%-twice, 6%-more than twice. Three percentages of
the patients continued to visit their physician ofﬁce in the second
year. Seventy-nine percent of the patients used at least 1 pre-
scription for TC treatment, and 73% used an antifungal oral
and/or topical agent. TC patients used an oral antifungal for 25
days on average. About 25% of the patients used an oral anti-
fungal as monotherapy, the most common therapy. Among oral
antifungals, griseofulvin was the most frequently used medica-
tion (41%), followed by terbinaﬁne (9%). Among newly diag-
nosed patients, 73% used prescription drugs in the ﬁrst year and
23% in the following year. CONCLUSIONS: TC patients used
medical services and prescription drugs substantially in the year
of diagnosis and many of these patients continuously used pre-
scription drugs due to relapse of the symptoms in the following
year. More effective therapy for TC could reduce the need for
subsequent therapy.
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There is a growing concern in the United States regarding antibi-
otic resistance due to inappropriate prescribing of antibiotics.
OBJECTIVES: Report the patterns of oral antibiotics ﬁlled fol-
lowing a medical visit for upper respiratory infection (URI) in a
state Medicaid population. METHODS: The study sample
included Medicaid recipients who had an outpatient or emer-
gency department (ED) visit in 2002 for an acute URI. Outpa-
tient and ED claims with a primary ICD-9-CM diagnosis code
for acute nasopharyngitis, acute pharyngitis, acute URI, acute
bronchitis, or inﬂuenza were extracted. Prescription claims for
antibiotics ﬁlled within ﬁve days following a URI-related medical
visit also were extracted. RESULTS: A total of 21,163 recipients
were included in the study. Over 71% of the recipients were
female, and nearly 95% were white. Recipients between 21 to
44 years of age accounted for more than half of the study group.
Nearly half of all recipients made only one visit for URI through-
out the year, and over 28% made 3 or more visits. Oral antibi-
otics accounted for roughly 10% of the total prescriptions ﬁlled
within 5 days following an acute URI-related medical visit. These
antibiotics were for penicillins (41%), cephalosporins (15%),
macrolides (11%), and others including quinolones, tetracy-
clines, sulfonamides and trimethoprim (33%). CONCLUSION:
One out of every ten prescriptions ﬁlled following an acute 
URI-related medical visit among recipients of Medicaid was for
an oral antibiotic. Many upper respiratory tract infections 
are viral in nature, in which oral antibiotic treatment may be
inappropriate.
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OBJECTIVE: To assess the validity and reliability of the self-
administered Spanish version of the LISAT 8 as a screening tool
for male ED in primary care settings. METHODS: A total of 653
subjects (537 ED and 116 nonED), >18 years, who reported
attempting sexual activity and managed at Primary Care level,
were extracted from a study designed to perform the cultural
adaptation and validation into Spanish of the LISAT 8. Multi-
variate logistic regression was applied to detect items or scale
domains capable to be predictors of ED, and the ROC curves
analysis to determine optimal cutoff score showing the best clini-
metric indicators for sensitivity, speciﬁcity and positive and neg-
ative predictive values to distinguish between ED and non ED
subjects. Positive and negative likelihood ratios, area under the
curve of the optimal cutoff score and kappa coefﬁcient of agree-
ment were also calculated. RESULTS: Items 2 and 8 of the check
list (satisfaction with sexual life and satisfaction with partner
relationship) which forms the affective domain of the instrument,
were found to be predictors for ED. Mean (+standard deviation)
for affective domain was signiﬁcantly higher in nonED than in
ED subjects; 9.2 + 2.1pts versus 5.6 + 1.8pts, p < 0.0001. This
domain showed moderate, but statistically signiﬁcant, correla-
tion coefﬁcients with IIEF and with each of its 5 domains (coef-
ﬁcients ranged between 0.44 and 0.69). ROC curves analysis
showed an optimal cutoff score for ED of <8pts; area under the
curve = 0.892, p < 0.0001; sensitivity, 0.87; speciﬁcity, 0.84; pos-
itive predictive value, 0.96; negative predictive value, 0.58; and
kappa agreement coefﬁcient = 0.602, p < 0.0001. CONCLU-
SION: The domain satisfaction with affective life (items 2 and
3) of the Spanish version of the LISAT 8 showed adequate clini-
metric properties of validity and reliability as a screening tool
for male erectile dysfunction in Primary Care level.
PSD2
ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD)
IN EUROPE:A PRELIMINARY INVESTIGATION
Williams VSL1, Fehnel SE1, Hogue SL2
1RTI-Health Solutions, Research Triangle Park, NC, USA;
2GlaxoSmithKline, RTP, NC, USA
OBJECTIVE: Sexual dysfunction is a common side effect of
selective serotonin reuptake inhibitor (SSRI) antidepressants.
Although widely acknowledged by US patients and physicians,
this side effect is not as readily recognized in Europe. The goal
of this study was to obtain preliminary estimates regarding the
prevalence and impact of ADSD in two European countries.
METHODS: This cross-sectional survey involved a total of 502
adults in France and the UK. All participants were taking an SSRI
that had been newly prescribed within the previous three
months. Information was gathered about patients’ current
depression treatment, other medications and conditions known
to impair sexual functioning, recent changes in sexual function-
ing, and the impact of any such changes. The Medical Outcomes
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Study Short Form–12 (SF–12) and the Arizona Sexual Experi-
ence Scale (ASEX) were also administered to measure health
status and current sexual functioning, respectively. From the
survey data, a set of four preliminary estimates of ADSD preva-
lence was developed for each country. RESULTS: Use of the most
liberal estimation algorithm resulted in 32.8% of the French
patients and 52% of the UK patients being classiﬁed as suffer-
ing from ADSD; 20.4% of the French sample and 21.6% of the
UK sample were categorized as having ADSD using the most
conservative algorithm. The study results also suggested that
ADSD negatively impacts patients’ quality of life. For example,
when patients were asked about the extent to which any changes
in their sexual functioning negatively affected their self-esteem
and relationships with sexual partners, signiﬁcant differences
were found between ADSD and non-ADSD subjects using all
four prevalence estimate deﬁnitions. CONCLUSION: The
results of this study suggest that both the prevalence and impact
of ADSD in Europe are substantial. A follow-up study with an
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OBJECTIVES: Pharmacological treatment with alpha1-blockers
is a method used to relieve benign prostatic hyperplasia (BPH)
symptoms. Non-selective alpha1-blockers, doxazosin (DOX) and
terazosin (TER), are currently available in generic and branded
forms; the selective alpha1A-blocker, tamsulosin (TAMS), is avail-
able branded only. This study compares total health care costs
(medical and pharmacy) for patients taking TAMS compared to
those receiving DOX or TER. METHODS: A retrospective
claims analysis was performed using a large national health
plan’s database for 1999–2001. Study population consisted of
males, 40 years or older, with an initial pharmacy claim date
(index date) for TAMS, DOX or TER during the identiﬁcation
period (2000). Cohorts were formed by drug received at index
date; generic and branded products were included. Propensity
score matching was used to balance cohort baseline characteris-
tics, for TAMS versus DOX (N = 1430) and TAMS versus TER
(N = 588) in separate intent-to-treat analyses. Health care costs
between cohorts for 12 months post-index date were collected
and compared as logarithmic average costs using multivariate
regression. RESULTS: In each analysis, propensity score match-
ing was successful in eliminating baseline population differences
for 28 variables related to demographics, comorbidities, health
care visits and costs except for 2 of 7 geographic region vari-
ables. The DOX analysis found no statistically signiﬁcant dif-
ferences in total costs or BPH-medical costs for TAMS ($5936
and $361) versus DOX ($5915 and $472), although pharmacy
costs were statistically signiﬁcantly higher (p < 0.05) for TAMS
($1798) versus DOX ($1583). The TER analysis found no 
statistically signiﬁcant differences in total costs, BPH-medical
costs, or pharmacy costs for TAMS ($5946, $378, $1896) versus
TER ($6807, $791, $1683), respectively. CONCLUSIONS: This
study demonstrates the importance of considering total health
care costs instead of only pharmacy costs when comparing
alpha1-blocker treatment for BPH. Differences in total and
medical costs for TAMS offset potential pharmacy cost beneﬁts
from DOX or TER.
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